Medicare GLP-1 Bridge statistics
The CMS GLP-1 Bridge sets a flat $50 a month for qualifying Part D members, according to GLP Chart, checked August 10, 2026.
The numbers
- The CMS GLP-1 Bridge sets a flat $50 a month for qualifying Part D members. (CMS, https://www.cms.gov, August 10, 2026)
- 3 products are covered: Wegovy, Foundayo, the Zepbound KwikPen. The pen counts. The Zepbound vials do not.. (CMS, August 10, 2026)
- The window opened July 1, 2026 and closes December 31, 2027. (CMS, August 10, 2026)
- 10 of the 51 state Medicaid programs cover Wegovy for obesity on limited terms, a separate program the Bridge does not change. (GLP Chart Medicaid corpus, August 28, 2026)
What we do not have
CMS has published no enrolment or uptake figure for the Bridge. GLP Chart does not have one, and will not estimate one. When CMS publishes, the number lands here with its source.
The Bridge, term by term
| Measure | Value | Detail | Source |
|---|---|---|---|
| Flat monthly price | $50 | Qualifying Part D members, prior authorization required | CMS |
| Covered products | Wegovy, Foundayo, the Zepbound KwikPen | The pen counts. The Zepbound vials do not. | CMS |
| Window opens | July 1, 2026 | Qualifying Part D members only | CMS |
| Window closes | December 31, 2027 | No renewal announced | CMS |
| Fill quantity | One monthly supply per fill | One fill = a single monthly supply of 28 or 30 days. CMS verbatim: 'Beneficiaries who are approved for coverage under the Medicare GLP-1 Bridge may obtain a single monthly supply (28 or 30 days) of an eligible GLP-1 product per fill. Sixty or ninety-day fills are not available.' Verified 2026-07-19 on the Information for Pharmacies page. This RESOLVES the open per-fill vs per-month question: CMS says '$50 copay' and the site renders '$50 a month', and because no fill exceeds one monthly supply those are the same number. The site wording is correct. | CMS |
| Low Income Subsidy | Does not reduce the price | No low-income subsidy on Bridge drugs. CMS verbatim: 'there is no low-income subsidy (LIS) provided for LIS beneficiaries'. Extra Help does NOT reduce the $50. Verified 2026-07-19 at cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge. FRAMING RULE: do not write this as a loss. Part D never covered a weight-loss GLP-1 (2003 statute), so an Extra Help beneficiary is not losing a cheaper price they would otherwise have had; their alternative is the cash market at $149+. It is an expectation correction. Extra Help DOES apply on the regular Part D route (T2D / OSA / MASH), which is why the checker states it on both screens with opposite valence. | CMS |
Download this table: CSV or JSON. Free to reuse under CC BY 4.0 with a link. Nothing to sign up for.
Cite or embed this
Medicare GLP-1 Bridge statistics, GLP Chart, September 4, 2026. glpchart.com/stats/medicare-glp1-bridge-statistics/
<a href="https://glpchart.com/stats/medicare-glp1-bridge-statistics/">Medicare GLP-1 Bridge statistics</a>. Data: GLP Chart, September 4, 2026
Prices behind these figures come from each program's own published pricing page, checked every Monday. The current numbers live on the price index, and the dated monthly release is the GLP-1 Cash Price Index, September 2026. For any other cut of the data, email press@glpchart.com and you will have it within 24 hours.
The other statistics pages
- GLP-1 prices by state. What the cheapest verified cash GLP-1 route costs in each US state, and which states have fewer programs to choose from.
- GLP-1 cash prices over time. Every month since the weekly record opened, with the compounded and branded floors beside it.
- GLP-1 insurance coverage by payer. How 21 US insurers treat GLP-1s across the payer policies GLP Chart has read.
- Medicaid GLP-1 coverage by state. What each state Medicaid program covers, read from its own preferred drug list.
- Compounded versus branded GLP-1 spread. The gap between the cheapest verified compounded route and the cheapest verified branded route, month by month.
- GLP-1 shortage history. What the FDA shortage database says about each GLP-1 molecule today.